logo
Scientists are growing T. rex leather in a lab. It could be used to make purses.

Scientists are growing T. rex leather in a lab. It could be used to make purses.

The next time you go shopping for a new purse, your choices could go beyond traditional materials such as leather, nylon, cotton and polyester to include … Tyrannosaurus rex skin?
Yes, the remnants of the prehistoric predator are being used to create synthetic T. rex leather, which can be turned into accessories including purses. That's the plan for a trio of companies – The Organoid Company, Lab-Grown Leather Ltd., and VML – working on "a high-quality alternative to traditional leather that's cruelty-free and eco-friendly," said the collaborators in an April 25 news release.
The goal of a "luxury fashion item," hitting later this year, would be the first example of leather developed from an extinct species, the companies said.
"With T-Rex leather we're harnessing the biology of the past to create the luxury materials of the future," said Bas Korsten, global chief creative officer, Innovation & CCO EMEA at VML, the agency behind the 2024 Super Bowl "Mayo Cat" campaign and 2023's Mammoth Meatball, made of lab-grown meat.
Cosmos 482: Here's when the Soviet-era spacecraft may return to Earth
The team at The Organoid Company, a Netherlands-based biotech, will use fragments of T-Rex collagen protein recovered from fossils to recreate the prehistoric protein and engineer the new DNA into specialized cells for leather production. Another biotech company, the U.K.-based Lab-Grown Leather Ltd., will then use those specialized cells to produce skin, made with the T-Rex collagen protein, which is then tanned to form T-Rex leather.
"This project is a remarkable example of how we can harness cutting-edge genome and protein engineering to create entirely new materials," said The Organoid Company CEO Thomas Mitchell.
T. Rex leather could serve as a more environmentally friendly option to traditional leather and also eliminate "animal cruelty concerns," the companies said.
But some detractors consider the project misleading. University of Maryland vertebrate paleontologist Thomas Holtz, Jr. pointed out to Live Science, a science news site, how the lab-created skin won't be authentic because there's no actual T. rex skin or DNA to serve as a basis. "What this company is doing seems to be fantasy," he said.
Calling the announcement a "gimmick," Tom Ellis, professor of synthetic genome engineering at Imperial College London, told NBC News, 'I doubt that our knowledge of dinosaur evolution is good enough to be able to design a collagen gene specifically from T. rex."
But researchers have found collagen in an 80-million-year-old Tyrannosaurus rex fossil and that can be used as a template, they say.
The Organoid Company is creating a T-Rex protein by using fragments of the T-Rex collagen protein from fossils, the companies said in a statement to USA TODAY.
"An important distinction is that (the companies) are starting with the language of proteins, amino acids, rather than the DNA itself," according to the statement. "This encodes what the 3D structure looks like and from this they can then recreate or 'molecularly resurrect' the DNA which is put into special cell lines for leather production."
The result of this reconstruction of ancient protein sequences is T. Rex leather, which is structurally identical to T. rex skin. "A biomaterial inspired by prehistoric biology," Mitchell said.
Eventually, T. rex leather could be used beyond handbags and clutches to cover chairs and vehicle seats. "The production of T-Rex leather demonstrates VML's commitment to pioneering new grounds and shaping the future of our industry," Korsten said.
Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @mikegsnider.bsky.social & @mikesnider & msnider@usatoday.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Yahoo

timean hour ago

  • Yahoo

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif., June 04, 2025--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. "We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization," said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. "As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation." At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. "I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome," said Steve Gavel, Chief Commercial Officer at Orca Bio. "The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer." Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. "I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function," said Allison Frisbee, Senior Vice President, Legal at Orca Bio. "It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients." About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners. View source version on Contacts Corporate CommunicationsKelsey Grossmanmedia@ Investor RelationsJoshua Murrayir@

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Business Wire

timean hour ago

  • Business Wire

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. 'We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization,' said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. 'As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation.' At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. 'I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome,' said Steve Gavel, Chief Commercial Officer at Orca Bio. 'The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer.' Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. 'I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function,' said Allison Frisbee, Senior Vice President, Legal at Orca Bio. 'It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients.' About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Yahoo

timea day ago

  • Yahoo

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif., June 03, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enrolled, including 65 participants in the six to nine year-old primary analysis population and 11 participants aged 10 years or older. Study powering based on currently enrolled participants is approximately 80%. The rate of screening and randomization activities has materially increased with the recent activation of all study sites. A total of 108 NEAT participants have been screened to date with a low screen failure rate of 10%. All 37 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853/IEDAT-04-2022). Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study. Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Quince was granted FDA Fast Track designation for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of Quince's lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells; previously referred to as EryDex) in patients with A-T. Participants are randomized (1:1) between eDSP or placebo and treatment consists of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo. About Ataxia-Telangiectasia A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T. About eDSP for A-T eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment. eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions, including NDAs, and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store